Autopsy report · NCT01354951

Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy in Early Stage, Low Volume Prostate Cancer

“Lack of accrual”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 6 years 5 months before it stopped.
• 3 participants enrolled.
• Results were posted on the registry 1 year after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

Sponsor type

University, hospital or other

Conditions

Prostate Cancer

Interventions

Prostate Biopsy, Focal Brachytherapy , Assessment of QOL

Participants

3

Sites

3

Countries

United States

Trials that died the same way

• Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma
  “Lack of adequate accrual.” (92% match in meaning)
• Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth
  “Inadequate accrual” (90% match in meaning)
• Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
  “Severe lack of accrual” (90% match in meaning)
• Stereotactic Radiosurgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
  “poor accrual” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.